Keith W. Pratz, MD on Phase 3 VIALE-A Study in AML: How to Approach Patients @PennMedicine

Ask about FDA oncology approvals, clinical trials, and treatment guidelines.

Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission rates in treatment-naÃ¯ve acute myeloid leukemia patients.

https://library.ehaweb.org/eha/2020/eha25th/303390/courtney.dinardo.a.randomized.double-blind.placebo-controlled.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ddinardo

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →

ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →

PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →

Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →

News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →

News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →

Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →

Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →

Keith W. Pratz, MD on Phase 3 VIALE-A Study in AML: How to Approach Patients @PennMedicine

ASH 2025 AML Advances in 2026: PARADIGM Study, Menin Inhibitors, and Triplet Therapies for Acute Myeloid Leukemia

Joe Biden Prostate Cancer Timeline: When Did It Begin? Experts Weigh In

Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform

Keith W. Pratz, MD on Phase 3 VIALE-A Study in AML: How to Approach Patients @PennMedicine

Related Posts

ASH 2025 AML Advances in 2026: PARADIGM Study, Menin Inhibitors, and Triplet Therapies for Acute Myeloid Leukemia

Joe Biden Prostate Cancer Timeline: When Did It Begin? Experts Weigh In

Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform